急性冠脉综合征患者血清MCP-1、hsCRP水平及辛伐他汀的干预研究  

Effects of Simvastatin on serum monocyte chemoattractant protein-1,high sensitivity C-reactive protein in patients with acute coronary syndromes

作　　者：曲巍[1] 谢煜彤 

机构地区：[1]辽宁省沈阳市第四人民医院,辽宁沈阳110031

出　　处：《中国当代医药》2009年第23期54-55,共2页China Modern Medicine

摘　　要：目的:探讨辛伐他汀对急性冠脉综合征(ACS)患者血清单核细胞趋化蛋白-1(MCP-1)、超敏C反应蛋白(hsCRP)的影响。方法:采用酶联免疫吸附法(ELISA)和免疫比浊法分别检测了30例UA患者服用辛伐他汀前后血清MCP-1及hsCRP水平。结果:ACS患者血清MCP-1及hsCRP水平显著高于对照组,服用辛伐他汀4周后血清MCP-1及hsCRP水平下降。说明辛伐他汀可降低ACS患者血清MCP-1及hsCRP水平。结论:ACS患者血清MCP-1及hsCRP水平升高与冠脉炎症反应相关,辛伐他汀可明显降低ACS患者血清MCP-1及hsCRP水平,改善冠心病患者的预后。Objective ：To investigate the effects of simvastation on serum monocyte chemoattractant protein-1 （MCP-1）,high sensitivity C-reactlve protein （hsCRP）in Patients with acute coronary syndromes.Methods：Serum MCP-l ,hsCRP were detected by enzyme linked immunosorbent assay （ELISA）and turbidmetric 4 weeks before and after oral administration of simvastatin in 30 patients with ACS.Results： The contents of serum MCP-1, hsCRP in patients with ACS were significantly increased compared with health individuals （P〈0.01）.A significant decreased serum MCP-1 ,hsCRP were observed 4 weeks after simvastatin-taken （P〈0.01）.Conclusion：The MCP-1 plays important roles in the prognosis in patients with ACS. Simvatatin has a beneficial on decreasing serum MCP-1, hsCRP and alleviating inflammatory reaction in patients with ACS.

关 键 词：辛伐他汀 急性冠脉综合征 单核细胞趋化蛋白-1 超敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]